Targeting the Mechanisms of Resistance to Chemotherapy and  Radiotherapy with the Cancer Stem Cell Hypothesis by Morrison, Ryan et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2011, Article ID 941876, 13 pages
doi:10.1155/2011/941876
Review Article
Targeting the Mechanisms of Resistance to Chemotherapyand
Radiotherapy with the Cancer Stem Cell Hypothesis
Ryan Morrison,1 Stephen M. Schleicher,2 YunguangSun,2 KennethJ. Niermann,2
SungjuneKim,2 DanielE.Spratt,2 ChristineH.Chung,3 andBoLu2
1Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25701, USA
2Department of Radiation Oncology, Vanderbilt University School of Medicine, Vanderbilt University Medical Center and
Vanderbilt-Ingram Cancer Center Nashville, 1301 22nd Avenue South, B-902 TVC, Nashville, TN 37232-5671, USA
3Department of Hematology/Oncology, Vanderbilt University School of Medicine, Vanderbilt University Medical Center and
Vanderbilt-Ingram Cancer Center Nashville, 1301 22nd Avenue South, B-902 TVC, Nashville, TN 37232-5671, USA
Correspondence should be addressed to Bo Lu, bo.lu@vanderbilt.edu
Received 5 July 2010; Accepted 14 September 2010
Academic Editor: Shih Hwa Chiou
Copyright © 2011 Ryan Morrison et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Despiteadvancesintreatment,cancerremainsthe2ndmostcommoncauseofdeathintheUnitedStates.Poorcureratesmayresult
fromtheabilityofcancertorecurandspreadafterinitialtherapieshaveseeminglyeliminateddetectablesignsofdisease.Agrowing
body of evidence supports a role for cancer stem cells (CSCs) in tumor regrowth and spread after initial treatment. Thus, targeting
CSCs in combination with traditional induction therapies may improve treatment outcomes and survival rates. Unfortunately,
CSCs tend to be resistant to chemo- and radiation therapy, and a better understanding of the mechanisms underlying CSC
resistance to treatment is necessary. This paper provides an update on evidence that supports a fundamental role for CSCs in
cancer progression, summarizes potential mechanisms of CSC resistance to treatment, and discusses classes of drugs currently in
preclinical or clinical testing that show promise at targeting CSCs.
1.Introduction
Individualized cancer treatment has been an attractive con-
cept since the beginning of cancer research. Breakthroughs
inresearchhaveallowedthecharacterizationofmalignancies
accordingtotheiruniquegeneexpression,whichhasallowed
the pragmatic targeting of many cancer types based on their
speciﬁc gene expression patterns. For example, trastuzumab
improves the overall and progression-free survival in human
epidermal receptor 2- (Her2-) positive breast cancer [1–3].
The receptor-speciﬁc monoclonal antibodies bevacizumab
[4, 5] and cetuximab [6] have shown remarkable outcome
in vascular growth factor receptor- (VEGF-) positive and
epidermal growth factor receptor (EGFR)-positive cancer,
respectively. Examples of other targeted therapies [7–9]a r e
shown in Table 1. Indeed, the age of individualized cancer
therapy has begun.
Individualized proﬁling and targeting systems provide
novel tools to improve both prognostic accuracy and indi-
vidualized treatment for patients [10]. In addition, each of
the classical pillars of cancer therapy—(1) surgical resection,
(2) chemotherapy, and (3) radiation therapy—has made
signiﬁcant technological strides, and numerous clinical
studies have improved our ability to eﬀectively apply
and combine these modalities. Vaccines that prevent the
spread of the human papilloma virus (HPV) promise to
dramatically reduce cervical cancer; conversely, viruses are
being developed that directly attack carcinogenic cells [11].
Advancements such as functional imaging, magnetic reso-
nance imaging, immunohistochemistry, and ﬂow cytometry
have recently reﬁned our ability to tease out, subdivide,
prognosticate, and deﬁne the myriad of permutations in
this uniquely complex and malignant disease. A growing
arsenal of prevention strategies and screening technologies
has allowed physicians to diagnose and treat cancer earlier
in its progression than ever before. All of these evolving
modalities and strategies to manage cancer have helped
result in a pattern of continuously dwindling cancer-related
morbidity and mortality in the United States [12].2 Journal of Oncology
Table 1: Update on clinical trials for CSC molecular targets.
Target Drug Cancer Phase http://clinicaltrials.gov/ Sponsor
Identiﬁer
Wnt Resveratrol Colon I, II NCT00256334 University of California, Irvine
Notch MK0752 Breast I NCT00106145 Merck
Pancreatic I, II NCT01098344 Cancer Research UK
RO4929097 Renal cell II NCT01141569 University Health Network, Toronto
PF-03084014 Leukemia I NCT00878189 Pﬁzer
Hedgehog GDC-0449 Solid tumors I NCT00968981 Genentech
Colorectal II NCT00636610 Genentech
PF-04449913 Hematologic I NCT00953758 Pﬁzer
BMS-833923 Basal cell I NCT00670189 Bristol-Myers Squibb
LDE225 Medulloblastoma I NCT00880308 Novartis
However, despite this progress, cancer remains the 2nd
most common cause of death in the United States [13]. Our
continuing inability to cure cancer is largely attributed to the
ability of cancer cells to spread and repopulate after initial
therapies have eliminated all detectable signs of disease.
New interventions that reduce this capacity could have a
far-reaching impact on our ability to prevent recurrences,
extend survival, and cure many types of cancer. Thus, better
understanding the mechanisms of cancer progression for
the development of antirepopulation therapies is likely to
oﬀer signiﬁcant clinical beneﬁt. The cancer stem cell (CSC)
hypothesis has emerged within this line of investigation.
This hypothesis has helped explain how cancer might recur
and metastasize despite eﬀective initial treatment and thus
represents a promising new front in the war on cancer.
2.The CSCHypothesis
A paradigm shift in our understanding of cancer tumori-
genesis emerged in 1994 when John Dick and colleagues
demonstrated that human acute myeloid leukemia (AML)
has a hierarchical organization that originates from a
primitivehematopoieticcell[14].Thispopularizedaconcept
ﬁrst proposed over a century ago: that cancer growth within
a given neoplastic process may be dependent upon only a
small fraction of progenitor cells [15, 16]. These cancer cells
that retain their normal stem cell properties of self-renewal
and pluripotency are often referred to as CSCs. Within the
framework of the CSC hypothesis, normally dormant stem
cells may inadvertently acquire tumorigenic DNA mutations
and become CSCs which inappropriately begin dividing and
direct the neoplastic process. Multiple studies have recently
providedcompellingsupportoftheCSChypothesis[17–19].
Despite controversies surrounding the CSC hypothesis
[20, 21], substantial evidence has emerged that supports
its role in cancer including AML [22], brain [23], breast
[24], colon [25] ,h e a da n dn e c k[ 26], lung [27], liver
[28], melanoma [29], pancreatic [30], prostate [31], and
squamous cell [32]c a n c e r( Figure 1). At least 15 drugs
designed to exploit the CSC hypothesis have entered clinical
trials [33]. However, the CSC hypothesis has not been fully
established and will likely evolve as unknown molecular
targets capable of promoting tumorigenesis continue to
be discovered [34]. Moreover, the translation from the
theoretical beneﬁt of CSC eradication into its actual clinical
beneﬁt has to be experimentally demonstrated. Another
poorly understood nuance is that certain cancer types may
be relatively independent of fractional CSC populations,
operatingmoreconsistentlywithclassicalstochasticorclonal
evolution models [35]. Although there are limitations to
the CSC hypothesis, it is evident that cancer often possesses
functionally deﬁned CSCs, and is likely to be at least partially
dependent on CSCs for growth and survival.
In cancer types where neoplastic growth and diﬀer-
entiation depend on CSCs, complete eradication of this
population may be curative. Furthermore, agents that
force CSCs to rapidly diﬀerentiate en masse within such
cancer types may limit disease progression. Alternatively,
suppressing residual CSCs after initial tumor debulking may
sustain remissions and extend the progression-free survival
of patients receiving CSC suppressive therapy. Considering
these distinct therapeutic potentials of targeting CSCs, it
appears that CSC-targeted therapies could be an eﬀective
complement to traditional treatment approaches such as
surgery, chemotherapy, and radiation therapy. Indeed, it
is possible that these traditional strategies leave behind
residual CSCs which are capable of spreading and regener-
ating tumors, leading to cancer recurrence and metastasis.
Moreover, these recurring tumors often acquire resistance to
chemotherapy and radiation [36, 37]. Multiple investigators
have demonstrated the ability of CSCs to develop resistance
traits after induction chemo- and radiation therapy.
Evidence suggests that CSCs are highly heterogeneous
[38, 39]. This heterogeneity may be responsible for the evo-
lution of resistance to ﬁrst-line therapies in recurrent cancer
since treatment-resistant cells within a heterogeneous tumor
population may be selected for during induction therapy.
The outcome may be a more aggressive and treatment-
resistant malignant recurrence [36]. In addition, CSC het-
erogeneity may make the pharmacological eradication of
the entire CSC population diﬃcult since these cells may
exhibit variable expression of drug-targeted genetic markers.Journal of Oncology 3
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Figure 1: Cell surface phenotype of cancer stem cells. A summary of cancer stem cells surface markers identiﬁed in a variety of cancer types.
This task is complicated by the possibility that cancer may
exhibit ﬂuctuating phenotypes, frequencies, and biological
properties within an individual patient [40]. Furthermore,
existing microenvironmental signaling pathways may recruit
or promote CSC functions, perhaps through neoplastic
clonal dediﬀerentiation processes [40, 41]. Until these chal-
lenges are overcome, CSC-targeting therapies will not reach
theirfullpotential.Regardless,researchsurroundingtheCSC
hypothesis has already helped generate numerous potential
pharmacological interventions, and combinations of these
CSC-speciﬁc therapeutic approaches with traditional cancer
treatment strategies may show synergistic beneﬁts since their
mechanisms of action are distinct and complementary.
3. FrequentCancer Recurrence May Be due to
thePreferentialKillingofDifferentiatedCells
While LeavingCSCsbehind
As previously mentioned, cancer recurrence may be partly
due to the fact that conventional therapies such as chemo-
and radiation therapy fail to speciﬁcally target CSCs.
Instead, these therapies likely enrich CSC populations by
preferentially killing diﬀerentiated cancer cells that had
little potential to sustain cancer growth. Numerous studies
indicate that CSCs are resistant to chemo- and radiotherapy
and are therefore preferentially preserved when cancer cells
are targeted by these approaches [15, 42–45]. Interestingly,
during diﬀerentiation therapy for the treatment of acute
promyelocytic leukemia (APML), all-transretinoic acid and
arsenic trioxide are used to induce the diﬀerentiation of
CSCs down their hematopoietic lineage. The outcome is
dramatically reduced self-renewal capacity and extended
patient survival [46]. The dramatic anticancer eﬀects of
combined modality diﬀerentiation therapy in leukemia also
demonstrate how synergy between independent therapeutic
approaches can achieve remarkable outcomes in cancer
therapy[47].Thus,diﬀerentiationtreatmentofAPMLserves
to illustrate (1) the relative impotence of diﬀerentiated cells
in cancer, (2) the potential therapeutic beneﬁt of speciﬁcally
targeting CSCs, and (3) the potential synergy between CSC-
speciﬁc therapies and existing modalities.
4. The Detection and Identiﬁcation of CSCs
In recent years, an eﬀort has been made to successfully
identify stem cells in multiple human malignancies, includ-
ing hematological, breast, colorectal, brain, pancreatic, and
maxillofacial cancer [22, 25, 32, 34, 36, 48–50]. Much
attention has been directed to speciﬁc cell-surface proteins.
Among these, CD133/prominin-1 is a cell-surface molecule
thought to be a stem cell marker for multiple cancer types,
including CNS, colon, hepatocellular, pancreatic, prostate,
and renal cancer [51]. Eramo et al. demonstrated that freshly
excised small cell and nonsmall cell lung cancers tissues
contain a small subset of CD133-positive cells capable of
generating long-term lung tumor spheres in vitro and diﬀer-
entiating into tumors in vivo. Matsumoto et al. elucidated a
mechanistic relationship between CD133 and the hypoxia-
inducible factor-1α (HIF-1α), a downstream molecule in
the mammalian target of rapamycin (mTOR) cell signaling4 Journal of Oncology
pathway, suggesting a role for mTOR in the regulation of
CD133 expression [52].
In addition to cell-surface markers, many investigators
have focused on the selective overexpression of certain
genes normally present in progenitor cells. Leukemia cells,
which have been transformed from the normally present
“partially committed” cells responsible for physiological
cellular maintenance, undergo mutations that result in self-
perpetuatedrenewalcapabilities.Thesecellscanbeidentiﬁed
by selective gene overexpression [24, 53–57]. In an attempt
to link cellular pathways to gene expression patterns in
lung CSCs, Stevenson et al. compiled and tested a model
of 100 signature genes to determine embryonic stemness.
Cells with a high embryonic stemness score were found
to aﬀect multiple cellular processes, including Ras, Myc,
chromosomal instability, and cellular invasiveness [58]. Seo
and colleagues demonstrated increased expression of 13
genesinside-population(SP)A549nonsmallcelllungcancer
cells, as compared to non-SP cells [59].
Interestingly, Glinsky has developed a novel clinical
model to assess the relative “stemness” of cancer cells by
quantifying gene expression signatures, and he has shown
that this model may predict therapeutic outcomes. The
“BMI1 pathway” algorithm is based on a collective signature
of 9 individual gene characteristics: TEZ, EED pathway,
Suz12/POLII, Suz12, Nanog/Sox2/Oct4, PcG-TF, BCD-TF,
ESC pattern, and BMI1 pathway. This multifactorial model
allowed the stratiﬁcation of patients into high-risk and low-
risk groups in a retrospective analysis of large cohorts of
breast, prostate, lung, and ovarian cancer patients [60]. It
remains to be conﬁrmed whether an individual cellular
marker can accurately identify normal stem cells or CSCs or
whether a multifactorial phenotypic model is required.
5. Mechanismsof CSC Resistance to
Chemotherapy and Radiation
CSCs have been found to exhibit a number of genetic and
cellular adaptations that confer resistance to classical ther-
apeutic approaches. These include relative dormancy/slow
cell cycle kinetics, eﬃcient DNA repair, high expression
of multidrug-resistance-type membrane transporters, and
resistance to apoptosis (Figure 2). Cancer often acquires
resistance to chemo- or radiotherapy after nonlethal expo-
sure [36]. This process likely represents the natural selec-
tion of resistant CSCs. Radiotherapy and most types of
chemotherapy exert their antineoplastic function by dis-
rupting cancer cell DNA integrity; therefore, it is possible
that the oncogenic resistance of CSCs results from increased
expression of DNA integrity-maintenance systems [61]. In
addition, increased expression of drug eﬄux pumps may
promote oncogenic resistance against cytotoxic chemother-
apeutic agents [62, 63].
5.1. Resistance to DNA Damage within CSCs. Normal, non-
cancerous stem cells exhibit well-fortiﬁed DNA mutation
defense systems that typically serve to prevent mutation
into carcinogenic CSCs. Unfortunately, when mutations that
create CSCs do occur, the inherent defense systems of stem
cells serve to protect them from DNA-targeting chemo- and
radiation therapy. The chemo- and radioresistance of CSCs
has now been demonstrated in numerous experiments [64],
although the mechanisms underlying this resistance are not
fully understood. In one experiment, radiation was shown to
causeequallevelsofdamagetoallcancercells,butCSCswere
able to repair this damage more rapidly [15].
One potential modulator of CSC resistance to DNA-
targeting agents is the family of checkpoint kinases 1/2
(Chk1/2 kinases), which become activated after genotoxic
stress and arrest the cell cycle to allow DNA repair. These
kinases have higher basal and inducible activities in CSCs
than in nonstem cells [65]. Supporting the role of Chk1/2
kinases in CSCs, Chk1/2 inhibitors partially reverse the
resistance of glioblastoma CSCs to radiation-induced cell
death [65, 66].
InadditiontoaugmentedDNArepairsystems,CSCsmay
also exhibit changes in telomerase function, which allows
resistance to chromosomal degradation in these rapidly
dividing cells. Telomerase is a complex ribonucleoprotein
enzyme that synthesizes and maintains telomeric repeats at
the ends of chromosomal strands [67]. Sustained telomerase
function is critical in conferring cellular immortality, as
telomeres are otherwise shortened with each cell division,
eventually triggering cellular senescence. Telomerase func-
tion was recently shown to be downregulated in brain CSCs,
and several drugs that interfere with telomerase function
are already in clinical trials, including arsenic trioxide,
GRN163L, and vaccines [68–72].
5.2. Resistance to Drug Penetration into CSCs. An important
component of the DNA integrity defense systems in normal
stem cells is the relatively high expression of eﬄux trans-
porters from the ATP-binding cassette (ABC) gene family
[73]. These pumps allow normal stem cells to preserve
their genome more eﬀectively against chemical mutagens
in an attempt to prevent carcinogenesis. Similar to the
way that CSCs may derive resistance to DNA damage from
the preexisting DNA repair systems in normal stem cells,
CSCs may also derive resistance to chemical mutagens
(e.g., chemotherapy) through the expression of drug eﬄux
pumps in normal stem cells from which they were derived.
Moreover, the relatively high expression of these transporters
may be used to identify CSCs within a neoplasm [74]. Drugs
that block the function of eﬄux transporters or that down-
regulate their expression have the potential to overcome
CSC chemoresistance. Although multidrug transporters are
not likely to signiﬁcantly inﬂuence the direct cytotoxicity of
radiation-based therapies, chemotherapy or chemoradiation
therapy may beneﬁt from blockade of multidrug eﬄux
pumps in CSCs.
5.3. Resistance to Apoptosis within CSCs. Resistance to ther-
apy might also be conferred to CSCs through the activation
of the Akt pathway [75, 76] and the overampliﬁcation of
apoptosis inhibitor proteins. This was ﬁrst demonstrated
in chemoresistant hepatocellular carcinoma CSCs, which
were found to preferentially activate Akt/PKB and bcl-2Journal of Oncology 5
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Figure 2: Schematic diagram of the mechanisms leading to cancer stem cell resistance to chemo- and radiation therapy. Cancer stem cells
have been found to exhibit a number of genetic and cellular adaptations that confer resistance to classical therapeutic approaches, including
relative dormancy/slow cell cycle kinetics, eﬃcient DNA repair, high expression of multidrug-resistance-type membrane transporters,
resistance to apoptosis, and protection by a hypoxic niche environment.
cell survival pathways [77]. Moreover, inhibition of Akt by
perifosine sensitizes CSCs to radiation-induced apoptosis
[78]. This suggests that characterization of Akt and bcl-
2 expression in CSCs may have signiﬁcant clinical utility.
FMS-like tyrosine kinase 3 (FLT3) receptor signaling is an
important hematopoietic growth pathway upstream of Akt.
FLT3 receptors are often mutated in AML and are associated
with a high relapse rate and poor prognosis [79]. Inhibition
of FLT3 signaling with CEP701 reduces the tumorigenicity
of xenografts [80], and CEP 701 has reached phase 2 clinical
trials [81].
The mitochondrial pathway of apoptosis is triggered by
cytochrome c release and second mitochondria-derived acti-
vator of caspase (Smac) activation [82]. Smac, in association
with Direct Inhibitor of Apoptosis Binding Protein with low
pI (Smac/DIABLO), promotes apoptosis via neutralization
of inhibitor of apoptosis (IAP) proteins [82]. Most human
cancers have high levels of IAPs, including the X-linked
inhibitor of apoptosis protein (XIAP) isoform, which are
associated with poor treatment responses [83]. Based on
these observations, Vellanki et al. found that the inherent
radioresistance of glioblastoma CSCs could be alleviated by
promoting apoptosis with an XIAP inhibitor. Importantly,
this treatment had no undesirable radiosensitizing eﬀects on
normal rat neurons or glial cells [84]. This provides another
promisingpathwayfortherapeuticinterventiontargetingthe
apoptotic regulation of CSCs.
Another promising molecular target to promote apop-
tosis in CSCs is nuclear factor κB( N F κB). NFκBi sa
transcription factor believed to be intricately involved in the
development and progression of certain cancer types [85].
N u c l e a rf a c t o rn B( N F n B ) ,ac o u s i no fN F κB, is an anti-
apoptotic transcription factor that is activated in leukemias
[86, 87], pancreatic adenocarcinoma [88], and melanoma
[89].Althoughthesenuclearfactorsarenotaswellstudiedas
Akt, they may oﬀer promising drug targets. NF-κB inhibitors
include NPI-0052 (salinosporamides A), which is in phase I
clinical trials, and TDZD-8 (parthenolide), which is still in
preclinical testing.
5.4. The Microenvironment and CSCs. Oxygen is a well-
known radiosensitizing agent due to its ability to form
radiation-induced reactive oxygen species that can damage
DNA. Accordingly, radioresistance in breast CSCs may be
mediated by increased production of free-radical scavengers
[37].Considering thedependenceofradiotherapy onoxygen
free radicals, it has long been postulated that areas of low
oxygen tension within tumors create microenvironments
that are relatively protected from radiation-induced damage
[44]. Unexpectedly, it was discovered that CSCs reside
along perivascular areas [90] and are thus likely to be
well oxygenated [15]. This may help explain the eﬃcacy
of antiangiogenic therapies such as bevacizumab in that
such therapies may be CSC-speciﬁc. Theoretically, CSC
compartment hypoxia may be induced by antiangiogenic
therapies, conferring radioresistance to the CSCs, although
this has yet to be demonstrated in vivo, and the clinical
signiﬁcance of this remains unknown. Still, we speculate that
radiation might be more eﬀective in treating cancer if it is
administered before any antiangiogenic chemotherapies are
applied.
Vermeulen and colleagues recently discovered another
interesting role of the microenvironment, speciﬁcally in
the promotion of cancer cell stemness. They found that
high Wnt pathway signaling functionally deﬁnes colon CSCs
[91]. Importantly, Wnt signaling in these cells depended on
costimulation by c-Met signaling. Activated myoﬁbroblasts
in the tumor microenvironment were responsible for c-
Met activation through production of hepatocyte growth
factor (HGF) [91]. Thus, inhibition of stromal-produced
HGF or the subsequent activation of c-Met signaling via c-
Met inhibitors may represent additional approaches to target
CSCs [92].6 Journal of Oncology
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irradiation, thus allowing tumor cells to both survive after irradiation and develop additional adaptive mutations. ICG-001, PKF115-854,
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6. Induction Therapy May Enrich CSCs
An important result of the well-documented CSC resistance
to radiation and chemotherapy is that these therapies often
serve to enrich the resistant CSC subpopulation, perhaps
even selecting for more resistant clones within a hetero-
geneous CSC population. Evidence of radiation-induced
enrichmenthasbeenshowninboth brain[15,45]andb r east
[42] CSCs. Furthermore, radiation has little eﬀect on the
ability of remaining CSCs to regrow tumors [15]. Thus, CSC
enrichment may be the basis for the relative inability of most
single modality cancer treatment strategies to control long-
term cancer growth. This pattern of initial response followed
by long-term failure is known as “the paradox of response
and survival in cancer therapeutics” [93]. CSC-speciﬁc
pharmaceutical interventions are being developed that may
eliminate both primary and acquired CSC chemoresistance.
This may dramatically improve the treatment of cancer by
abrogating the potential for CSC-induced tumor regrowth
and systemicdisease spread afterinitial treatment. Forexam-
ple, in experiments by Sung et al. showing that pancreatic
CSCs could survive and expand after serial exposures to
gemcitabine, this chemoresistance was overcome by the use
of CD44 or ABC transporter inhibitors [94].
Additional strategies to overcome therapeutic resistance
during cancer treatment are as follows.
6.1. Concurrent Therapy: The Key to CSC Eradication. It
is now well established that combination therapy helps
prevent the development of cancer resistance, except in a
select group of cancer types where a single pharmaceutically
correctable mutation exists [95]. For example, many clinical
trials have shown improvements in cancer survival with the
use of concurrent chemo- and radiation therapy [96]. This
likely reﬂects the broadly held belief that the best chance for
curing cancer is during the ﬁrst round of therapy before the
selection pressure promotes the evolution of resistant CSCs.
Inlaterroundsoftherapy,notonlyhasthecancerhadtimeto
grow and spread further, but it has also evolved resistance toJournal of Oncology 7
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previously encountered therapies. Unfortunately, coadmin-
istration of chemotherapy and radiation therapy is not
eﬀective against all types of cancer, and it is not always
feasible due to its potential signiﬁcant toxicity. Thus, it
will be important to design preclinical studies and clinical
trials that evaluate potential synergistic beneﬁts of adding
CSC-targeted therapies to traditional cancer regimens.
6.2. Surgical Resection Following Induction. As new data
supports a role for the CSC hypothesis in solid tumors in
addition to hematologic malignancies, outcomes following
the surgical resection of solid tumors may signiﬁcantly
improve. If induction approaches can be eﬀectively aug-
mented with anti-CSC therapies, then followup surgical
resection may show improved curative outcomes. Theoreti-
cally,CSC-speciﬁcinductionchemotherapiesshouldoﬀeran
immediate reduction in CSC metastatic potential and should
reduce any hematogenous and lymphatic CSC micrometas-
tases that would otherwise diminish the eﬃcacy of surgical
resection. Considering its powerful therapeutic potential,
CSC-targeted therapies may be particularly valuable in
surgically challenging malignancies such as pancreatic [97]
and brain [98]c a n c e r .
6.3. Targeting CSCs. In order to more eﬀectively target
CSCs, molecular proliferation and survival mechanisms of
CSCs must be better understood. Many institutions have
developed large banks of malignant tissues with coordinated
clinical data, and this resource is being actively mined.
Techniques for concentrating, isolating, and enriching CSCs
from resected tumors are also rapidly evolving, and cell
culture and xenograft models that allow us to transplant
and sustain CSCs are maturing. Finally, these advances
have been translated into the development of several ther-
apeutic opportunities. Here, we will review some of the
prominent classes of drugs that will potentially yield clinical
beneﬁts in the near future. An update of clinical trials
assessing these targets is illustrated in Table 1 (data from
http://clinicaltrials.gov/).
6.3.1. Wnt Inhibitors. Developmental pathways that direct
the diﬀerentiation of normal stem cells represent attractive
targets for drug discovery. In particular, the roles of Notch
and Wnt/β-catenin [99] signaling have been examined,
and both have been implicated in the development and
progression of several types of leukemia [100, 101].
For instance, Wnt signaling serves an important role in8 Journal of Oncology
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Figure 5: Schematic diagram of the Sonic Hedgehog signaling pathway. The hedgehog signaling pathway is a potential modulator of cancer
stem cell carcinogenesis with signiﬁcant therapeutic implications. GDC-0449, XL-139, and IPI-926 are drugs under development targeting
this signaling pathway.
promoting the proliferation of immature thymocytes [102].
The nonsteroidal anti-inﬂammatory drug (NSAID) etodolac
inhibitsWntsignalingandmaybeofbeneﬁtinthetreatment
of chronic lymphocytic leukemia [101]. In fact, all NSAIDS
may have anti-Wnt properties and thus potentially have
anticancer properties [99].
The Wnt/β-catenin pathway promotes genomic instabil-
ity and DNA damage tolerance that may be enhanced by
DNA damage in CSCs [15]. The pathway has been shown
to promote genomic instability in colon cancer [103]a n d
possibly promotes conversion of normal stem cells to CSCs
in gliomas [104]. Moreover, it has been shown that high
Wnt activity deﬁnes colon CSCs [91]. It has been postulated
that the Wnt/β-catenin pathway may promote genomic
instability after irradiation, thus allowing tumor cells to
both survive after irradiation and to develop additional
adaptive mutations. Wnt inhibitors have been designed to
therapeutically prevent this possibility and include ICG-
001, fungal derivatives PKF115-854 and CGP049090, as well
as monoclonal antibodies against Wnt-1 and Wnt-2 [105]
(Figure 3).
6.3.2. Notch Inhibitors. The Notch/γ-secretase/Jagged signal-
ing pathway is an important regulator of diﬀerentiation and
helps control cell fate [106]. The Notch ligands, Jagged 1
& 2 and Delta1 (D1) to Delta3 (D3), induce the release
of the Notch intracellular (Notch-IC) domain via enzy-
matic proteolytic cleavage by α-a n dγ-secretases. Notch-IC
translocates to the nucleus where it induces transcription of
Notch responsive genes [106, 107]. Notch signaling pathways
are activated in both breast CSCs [108] and in endothelial
cells [109] in response to radiation. Inhibition of Notch
signaling via γ-secretase inhibitors can potentially block CSC
self-renewal and decrease medulloblastoma growth [110],
and signiﬁcant eﬀorts to downregulate Notch signaling
are underway [111]. Currently available Notch signaling
inhibitors include MK-0752, a γ-secretase inhibitor that
is in clinical development for the treatment of leukemia
(Figure 4).
In addition to the classical Notch pathway, other rou-
tes may be used to modulate the carcinogenic potential
of elevated Notch signaling in CSCs. In particular, the
Delta/Notch-like epidermal growth factor-related receptor
(DNER) can be induced by histone deacetylase inhibition
to inhibit the growth of and induce the diﬀerentiation of
Glioblastoma neurospheres and xenografts [112]. This pro-
vides a basis for the manipulation of noncanonical signaling
pathways for therapeutic intervention against CSCs.
6.3.3. Hedgehog Inhibitors. The hedgehog signaling pathway
may represent an important modulator of CSC carcinogene-
sis with signiﬁcant therapeutic implications [113–117]. Sim-
ilar to Notch signaling, hedgehog signaling may also beneﬁt
from expanded drug discovery eﬀorts within noncanonical
pathways [118]. Already, hedgehog inhibitors have been
showntoinhibitmedulloblastomagrowthinmice[119],andJournal of Oncology 9
at least 3 diﬀerent hedgehog inhibitors have reached phase I
clinical trials (Figure 5).
6.3.4. Targeting the CSC Marker CD133. As mentioned
previously, the cell-surface molecule CD133 is believed to
be a stem cell marker for multiple cancer types [51]. Its
tumor-initiating function has been demonstrated in CNS
cancer, where only CD133+ cells from brain tumor biopsy
samples were able to reform tumors in in vivo mouse
models [120]. A recent study by Wang et al. demonstrated
the potential therapeutic use of targeting CD133 to direct
therapy speciﬁcally towards CSCs. They conjugated single-
walled carbon nanotubules (SWNTs), which allow localized
hyperthermia treatment, to anti-CD133 monoclonal anti-
bodies, and cultured these products with both CD133+ and
CD133− glioblastoma (GBM) cells. A mixture of CD133+
and CD133− cells were then exposed to near-infrared laser
light, and the CD133+ GBM cells were selectively destroyed.
Theyfoundinvivobeneﬁtsofthistechniqueaswellinmouse
models [121].
7. Concluding Remarks
With the advent of multidisciplinary approaches to cancer
therapy, signiﬁcant strides have been made in the treatment
of cancer. Now with new discoveries relating to CSCs, we
have yet another mechanism of therapeutic arsenal that may
prove beneﬁcial in combination with current therapeutic
modalities. The basic foundations for CSC-targeted therapy
are actively being discovered, and there are already several
pharmacologic agents available that are capable of specif-
ically modulating CSC intracellular signaling. Still, much
remains unknown about the basic signaling mechanisms of
CSCs that confer resistance to treatment, and better methods
for the disruption of CSC signaling must be developed
to fully integrate the CSC hypothesis into our treatment
paradigms. Interestingly, CSCs may not necessarily need to
be eradicated to prevent cancer progression if they can be
forced to diﬀerentiate down their lineage en masse as they do
in the treatment of APML. It is important for future studies
to focus on the discovery of new molecular targets for the
development of better pharmaceutical agents to eliminate or
diﬀerentiateCSCsandthattheseagentsbestudiedintandem
with traditional cancer therapies.
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